Correction: Oncobiotics in urinary bladder cancer. A narrative review of living cancer therapeutics Authors: Frontiers Production Office Published: 2026 Due to a production error, there were some mistakes in the published version, which have been corrected and are described below. The first sentence was rephrased for clarity. A correction has been made to the section Introduction: “Urinary bladder cancer (UBC) was among the most prevalent cancers worldwide, ranking seventh by five-year prevalence in 2020, with more than 1.7 million people living within five years of diagnosis.” A sentence was rephrased for clarify. A correction has been made to the section 3 LCT-mediated mechanisms of oncobiotics in UBC-oncotherapy, 3.1 Direct tumor destruction: “Species such as Listeria monocytogenes have been associated with reactive oxygen species (ROS) production and modulation of host immune responses, mechanisms that may contribute to antitumor activity (27), while Escherichia coli secretes cytolysin A, leading to membrane disruption and caspase-dependent cell death (28).” A correction has been made to Section 3.4 Oncolytic viruses (direct lysis and immune priming), Paragraph 2: “Early preclinical work established the feasibility of transcriptionally targeted oncolytic adenoviruses for bladder cancer. In 2002, Zhang et al. developed CG8840 by placing adenovirus type 5 under the control of the human uroplakin II promoter, thereby restricting viral replication to urothelial carcinoma cells. CG8840 demonstrated selective replication in malignant urothelial cells and significantly inhibited tumor growth in human bladder cancer xenograft models after intravenous or intratumoral administration (55). Although CG8840 itself was an early experimental construct, it provided important proof-of-concept for the later development of clinically advanced bladder cancer–specific oncolytic adenoviruses such as cretostimogene grenadenorepvec (CG0070).” Sievert, K.D., Amend, B., Nagele, U. et al. Economic aspects of bladder cancer: what are the benefits and costs?. World J Urol 27, 295–300 (2009). https://doi.org/10.1007/s00345-009-0395-z was not cited in the article. The citation has now been inserted in the section Introduction, Paragraph 1, after the sentence: “UBC is recognized as the cancer entailing the highest lifetime treatment costs per patient.” Lin NYT, Fukuoka S, Koyama S, et al. Microbiota-driven antitumour immunity mediated by dendritic cell migration. Nature. (2025) 644:1058–1068. doi: 10.1038/s41586-025-09249–8 was not cited in the article. The citation has now been inserted in the section 3.2.1 Innate-to-adaptive immune activation after the sentence: “Beyond classical bacterial species, emerging LCTs such as Hominenteromicrobium mulieris and Enterococcus gallinarum demonstrated the ability to stimulate dendritic cells and enhance cytokine production, leading to amplified innate antitumor immunity and improved responsiveness to immunotherapies” Miest T, Leibovich B, Bardot S, Young P, Boorjian S, Gonzalgo M, et al. 422 Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma. J Immunother Cancer. (2021) 9. doi: 10.1136/jitc-2021-SITC2021.422 was not cited in the article. The citation has now been inserted in Section 3.4 Oncolytic viruses (direct lysis and immune priming), after the sentence: “Beyond adenoviruses and VSV, other oncolytic viruses have demonstrated immunomodulatory potential. Intravesical administration of MV-NIS, an oncolytic measles virus encoding the sodium-iodide symporter, was evaluated in patients undergoing cystectomy and resulted in tumor downstaging and marked immune cell infiltration with minimal toxicity.” Binhui Biopharmaceutical Co., Ltd. OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer. ClinicalTrials.gov identifier: NCT05232136. Bethesda (MD): National Library of Medicine (US); updated August 12, 2024. Available from: https://clinicaltrials.gov/study/NCT05232136 was not cited in the article. The citation has now been inserted in 3.4 Oncolytic viruses (direct lysis and immune priming), after the sentence: “OH2, a genetically engineered herpes simplex virus type 2 expressing GM-CSF, combines direct oncolysis with immune stimulation and is currently under clinical evaluation in patients with NMIBC unresponsive to first-line intravesical therapy.” There was a mistake in Table 1 as published. In the “Developmental stage” column, the entry for CVA21 (CAVATAK) was erroneously given as “Phase I/II”. The correct developmental stage is “Phase I”. The corrected Table 1 appears below. Table 1Overview of living cancer therapeutics in urinary bladder cancer.Therapeutic platformType of LCTMechanism of actionRoute of administrationImmune effectsDevelopmental stageTranslational/clinical statusBCG (Bacillus Calmette–Guérin)Live attenuated bacteriaActivation of innate and adaptive antitumor immunityIntravesicalStrong activation of macrophages, NK cells, dendritic cells, and T cellsClinically establishedCurrent standard of care for high-risk NMIBCCG0070Oncolytic adenovirus expressing GM-CSFSelective replication in Rb-deficient tumor cells with GM-CSF-mediated immune activationIntravesicalPromotes immunogenic cell death and local immune stimulationPhase II/IIIPromising efficacy in BCG-unresponsive NMIBCCVA21 (CAVATAK)Oncolytic coxsackievirusSelective viral replication and tumor lysis via ICAM-1 targetingIntravesicalInduces tumor inflammation and immune gene upregulationPhase IEarly clinical proof-of-concept establishedNadofaragene firadenovecAdenoviral gene therapyDelivery of IFN-α2b gene to urothelial cellsIntravesicalEnhances interferon-mediated antitumor immunityFDA-approvedApproved for BCG-unresponsive NMIBCOH2Genetically modified HSV-2Direct oncolysis combined with GM-CSF-mediated immune activationIntratumoral / intravesicalEnhances immune cell recruitment and activationPhase I/IIUnder clinical evaluationMV-NISOncolytic measles virusSelective viral infection and tumor destructionIntravesical / intravenousPromotes immune infiltration and tumor inflammationEarly clinical developmentUnder clinical evaluationLactobacillus spp. (LGG, L. casei)Probiotic bacteriaImmune modulation and enhancement of antitumor immune signalingOral and intravesicalEnhances macrophage and neutrophil recruitmentPreclinical and clinical adjunct studiesPotential adjunctive immunomodulatory strategyEngineered Salmonella spp.Genetically modified bacterial vectorTumor-selective delivery of siRNA and immunomodulatory payloadsIntravesical / experimental systemic administrationIncreases CD8+ T-cell infiltration and immune activationPreclinicalPromising programmable delivery platformBifidobacterium infantis–HSV-TK systemEngineered probiotic suicide-gene therapyHSV-TK/ganciclovir-mediated induction of tumor apoptosisExperimental intravesical deliveryIndirect immune activation secondary to tumor apoptosisPreclinicalProof-of-concept demonstrated in animal modelsIL-15–engineered Salmonella VNP20009Synthetic bacterial immunotherapyLocalized IL-15/IL-15Rα cytokine deliveryIntravesicalStrong activation of NK cells and CD8+ T cellsPreclinicalHigh translational potential for immune enhancementMCNA (Mycobacterium phlei cell wall–nucleic acid complex)Bacterial-derived immunotherapyImmune stimulation and pro-apoptotic activityIntravesicalEnhances local immune activationEarly clinical evaluationInvestigated in BCG-unresponsive NMIBCBacteriobots (engineered E. coli Nissle 1917)Bioengineered bacterial microrobotsTargeted tumor localization and ROS-mediated tumor destructionExperimental local deliveryPotential secondary immune activationEarly preclinicalEmerging next-generation precision platform Overview of living cancer therapeutics in urinary bladder cancer. There was a mistake in Table 2 as published. In the “Treatment category” column, the following entries were erroneously given and have been corrected: KD01 (NCT07359235): “Intravesical viral immunotherapy” has been corrected to “Recombinant/oncolytic adenoviral therapy”. KD01 (NCT07359235): “Intravesical viral immunotherapy” has been corrected to “Recombinant/oncolytic adenoviral therapy”. VT-101 (NCT06632964): “Viral immunotherapy” has been corrected to “Recombinant/oncolytic adenoviral therapy”. VT-101 (NCT06632964): “Viral immunotherapy” has been corrected to “Recombinant/oncolytic adenoviral therapy”. ZH9 (NCT06181266): “Viral immunotherapy” has been corrected to “Salmonella enterica serovar Typhi–based bacterial immunotherapy”. ZH9 (NCT06181266): “Viral immunotherapy” has been corrected to “Salmonella enterica serovar Typhi–based bacterial immunotherapy”. Table 2Ongoing and emerging clinical trials of living cancer therapeutics and oncolytic platforms in bladder cancer.Clinical trial identifierTherapeutic platformTreatment categoryStudy statusDisease settingIntervention / strategyMain objectiveNCT06668493Nadofaragene firadenovecRecombinant adenoviral IFN-α gene therapyRecruitingLow-grade UTUCAdministration of nadofaragene firadenovec to the renal pelvisAssessment of safety and efficacy in upper tract urothelial diseaseNCT07332351 (TRIFECTA)Nadofaragene firadenovec + gemcitabine/cisplatin + durvalumabCombination gene-immunochemotherapyNot yet recruitingMIBCNeoadjuvant intravesical nadofaragene firadenovec combined with systemic chemotherapy and immune checkpoint inhibitionEvaluation of bladder-preserving multimodal neoadjuvant therapyNCT06510374Nadofaragene firadenovecRecombinant adenoviral IFN-α gene therapyRecruitingIntermediate-risk NMIBCIntravesical nadofaragene firadenovec versus observationPrevention of recurrence and disease progressionNCT06545955Nadofaragene firadenovec ± chemotherapy/immunotherapyCombination intravesical gene therapyRecruitingBCG-unresponsive NMIBCIntravesical nadofaragene firadenovec alone or combined with chemotherapy or immunotherapyEvaluation of enhanced antitumor efficacy and response durabilityNCT06253845CG0070Oncolytic adenoviral therapyActive, not recruitingIntermediate-risk NMIBCIntravesical CG0070 following TURBTReduction of post-resection recurrenceNCT04452591 (BOND-003)Cretostimogene grenadenorepvec (CG0070)Oncolytic adenoviral therapyActive, not recruitingHigh-risk BCG-unresponsive NMIBCIntravesical cretostimogene grenadenorepvec after BCG failureEvaluation of complete response durability and bladder preservationNCT05232136OH2Oncolytic HSV-2 therapyRecruitingNMIBCIntravesical OH2 oncolytic viral therapyPreliminary evaluation of intravesical oncolytic activityNCT06427291T3011Oncolytic viral therapyRecruitingNMIBCIntravesical instillation of T3011Evaluation of intravesical viral therapy efficacyNCT07359235KD01Recombinant/oncolytic adenoviral therapyRecruitingBladder cancerIntravesical administration of KD01Early clinical assessment of intravesical immunotherapyNCT06632964VT-101Recombinant/oncolytic adenoviral therapyRecruitingNMIBCVT-101 investigational therapyInvestigation of therapeutic activity in NMIBCNCT06181266ZH9Salmonella enterica serovar Typhi–based bacterial immunotherapyActive, not recruitingHigh-risk NMIBCIntravesical ZH9 treatmentPhase 1/1b assessment of dosing, safety, and preliminary efficacyNCT06833073 (V940-011 / INTerpath-011)Intismeran autogene (V940) + BCGPersonalized mRNA immunotherapyRecruitingHigh-risk NMIBC with CISPersonalized neoantigen mRNA immunotherapy combined with BCGEvaluation of recurrence prevention and immune response enhancement(Access 1 May 2026). Ongoing and emerging clinical trials of living cancer therapeutics and oncolytic platforms in bladder cancer. (Access 1 May 2026). The corrected Table 2 appears below. There was a mistake in Figure 4 as published. The title within the schematic contained a typographical error and was given as “Schematic of BCG Mechanisnssof Action in High-Grade Non–Muscle Invasive Bladder Cancer”. The title has been corrected to read “Schematic of BCG Mechanisms of Action in High-Grade Non–Muscle Invasive Bladder Cancer”. The corrected Figure 4 appears below. There was a mistake in the caption of Figure 1 as published. The publication-year range was erroneously given as “(2010 - 2025)”. The corrected caption of Figure 1 appears below: Number of publications using living cancer therapeutic with different types of oncobiotics of UBC from the last 15 years (2011-2025). Publication numbers were calculated using the PubMed database (2026, Jan 1st) using the keywords (oncobiotic OR "living cancer therapeutic" OR "live cancer therapeutic" OR "living therapeutic" OR "live biotherapeutic product" OR "oncolytic virus" OR virotherapy OR bacteriotherapy OR "bacterial therapy" OR "immune-modulating bacteria" ) AND ( "urinary bladder cancer"[MeSH] OR "bladder cancer" OR "bladder carcinoma" OR "urothelial carcinoma"). BCG mechanisms in high grade non-muscle invasive bladder cancer. “Number of publications using living cancer therapeutic with different types of oncobiotics of UBC from the last 15 years (2011–2025). Publication numbers were calculated using the PubMed database (2026, Jan 1st) using the keywords (oncobiotic OR “living cancer therapeutic” OR “live cancer therapeutic” OR “living therapeutic” OR “live biotherapeutic product” OR “oncolytic virus” OR virotherapy OR bacteriotherapy OR “bacterial therapy” OR “immune-modulating bacteria”) AND (“urinary bladder cancer”[MeSH] OR “bladder cancer” OR “bladder carcinoma” OR “urothelial carcinoma”).” The reference for Shi et al. (reference 47) was erroneously written as: “Shi Q, Geng J, Han L, Ji X, Li J, Mu Y, et al. Engineered Salmonella carrying siRNA-PD-1 shrinks orthotopically implanted bladder cancer in rats. J Drug Target. (2025), 1–9. doi: 10.1097/md.0000000000009292” It should be: “Shi Q, Geng J, Han L, Ji X, Li J, Mu Y, et al. Engineered Salmonella carrying siRNA-PD-1 shrinks orthotopically implanted bladder cancer in rats. J Drug Target. (2025), 1–9. doi: 10.1080/1061186X.2025.2512619” The publisher apologizes for the error and the original version of this article has been updated.